Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Medical Genetics · Glycogen Storage Disease Type III

GSD III Subtypes and Symptoms Over Time

At a Glance

Glycogen Storage Disease Type III is divided into two main subtypes: GSD IIIa affects the liver, muscles, and heart, while GSD IIIb only affects the liver. Symptoms evolve over a lifespan, shifting from childhood liver enlargement and hypoglycemia to adult muscle weakness in Type IIIa.

While all people with Glycogen Storage Disease Type III (GSD III) share a common challenge in breaking down stored sugar, the condition is divided into two primary subtypes based on which parts of the body are affected. Understanding whether you or your child has Type IIIa or Type IIIb is a key step in personalizing long-term care [1][2].

The Two Faces of GSD III: IIIa vs. IIIb

The difference between these subtypes depends on where the missing enzyme is active. Both types are caused by mutations in the AGL gene, but the location of the mutation on that gene determines the clinical path [3][4].

  • GSD IIIa (The Most Common Form): Affecting approximately 80-85% of patients, this subtype involves a lack of the glycogen debranching enzyme (GDE) in both the liver and the muscles (including the skeletal muscles and the heart) [5][6].
  • GSD IIIb: This subtype accounts for about 15% of cases. In GSD IIIb, the enzyme deficiency is limited to the liver. Because the muscles and heart still have active GDE, these patients typically do not develop the muscle weakness or heart complications seen in Type IIIa [1][7]. This subtype is often linked to mutations in a specific part of the gene called Exon 3 [8].

Why “Abnormal” Glycogen Causes Damage

To understand the physical impact of GSD III, it helps to look at the shape of glycogen. Normal glycogen is like a bushy tree with many branches that are easily “pruned” for energy. In GSD III, the body can only prune the very tips of these branches. What remains is a stunted, highly branched molecule called limit dextrin [9][10].

Because limit dextrin cannot be fully broken down, it physically crowds the inside of cells. Over time, this buildup can:

  1. Enlarge the Liver: In childhood, the liver becomes packed with limit dextrin, leading to hepatomegaly (an enlarged liver) [11][12].
  2. Weaken Muscles: In GSD IIIa, the buildup in muscle cells interferes with the cell’s ability to contract and repair itself, eventually leading to myopathy (muscle disease) [13][14].
  3. Thicken the Heart: The heart muscle may thicken (hypertrophy) as it becomes filled with limit dextrin, which requires regular monitoring by a cardiologist [15][16].

Symptoms Through the Lifespan

The “priority” of symptoms often shifts as a patient moves from infancy into adulthood.

Stage of Life Primary Symptoms & Focus
Infancy & Early Childhood Liver & Growth: The main concerns are low blood sugar (hypoglycemia), a noticeably enlarged abdomen from the liver, and slower-than-average physical growth [11][17].
Adolescence Stabilization: Interestingly, liver size often decreases and blood sugar levels may become easier to manage during the teenage years, sometimes leading to a false sense that the condition is “going away” [11][12].
Adulthood Muscle & Heart (GSD IIIa): For those with Type IIIa, the focus shifts to the muscles. Patients may notice progressive weakness, particularly in the hands and feet (distal weakness), or decreased stamina [14][18].

Managing the Progression

While the buildup of limit dextrin is a slow process, modern management focuses on “bypassing” the blockage. For example, a high-protein diet provides the muscles with a different type of fuel that doesn’t rely on the broken glycogen pathway, helping to preserve strength and heart function as the patient ages [19][2]. Regular follow-ups with a multidisciplinary team ensure that management strategies evolve alongside the patient [1][20].

Common questions in this guide

What is the difference between GSD IIIa and GSD IIIb?
GSD IIIa affects the liver, skeletal muscles, and heart, making it the most common form. GSD IIIb only affects the liver, so patients typically do not experience the muscle weakness or heart issues seen in Type IIIa.
What is limit dextrin and why does it build up in GSD III?
Limit dextrin is an abnormal, stunted form of glycogen that the body cannot fully break down due to a missing enzyme. It physically crowds inside cells over time, leading to liver enlargement and muscle weakness.
Do GSD III symptoms change as you get older?
Yes. In childhood, the main issues are usually low blood sugar and an enlarged liver. During adolescence, liver size often decreases, but in adulthood, patients with Type IIIa may develop progressive muscle weakness and heart issues.
How does a high-protein diet help manage GSD III?
A high-protein diet provides the muscles with an alternative source of fuel. This bypasses the broken glycogen pathway, helping to preserve muscle strength and heart function as the patient ages.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my (or my child's) genetic test show a mutation in Exon 3, and what does that mean for muscle and heart health?
  2. 2.At what age do you typically start seeing signs of muscle weakness or 'myopathy' in GSD IIIa?
  3. 3.What specific tests (like an EKG or echocardiogram) should we be doing to monitor heart health even if there are no symptoms?
  4. 4.Can you explain the difference between 'normal' glycogen and the 'limit dextrin' that builds up in GSD III?
  5. 5.Are there specific early signs of muscle weakness, like difficulty with stairs or running, that we should be watching for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.

    Hijazi G, Paschall A, Young SP, et al.

    Molecular genetics and metabolism reports 2021; (29()):100821 doi:10.1016/j.ymgmr.2021.100821.

    PMID: 34820282
  2. 2

    Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa.

    Olgac A, İnci A, Okur İ, et al.

    Annals of nutrition & metabolism 2020; (76(4)):233-241 doi:10.1159/000509335.

    PMID: 32712609
  3. 3

    [Analysis of two cases of glycogen storage disease type III due to compound heterozygous variants of AGL gene].

    Zhang M, Wang C, Xie Z, et al.

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2021; (38(11)):1073-1076 doi:10.3760/cma.j.cn511374-20200803-00578.

    PMID: 34729746
  4. 4

    Spectrum of amyloglucosidase mutations in Asian Indian patients with Glycogen storage disease type III.

    Perveen S, Gupta N, Kumar M, et al.

    American journal of medical genetics. Part A 2020; (182(5)):1190-1200 doi:10.1002/ajmg.a.61547.

    PMID: 32222031
  5. 5

    The Management and Clinical Outcomes of Pregnancy in a Female With Glycogen Storage Disease Type IIIA Caused by Rare Variant.

    Puente-Ruiz N, Palaniappan S, Woodall A, et al.

    JIMD reports 2025; (66(4)):e70030 doi:10.1002/jmd2.70030.

    PMID: 40606795
  6. 6

    Liver transplantation in patients with type IIIa glycogen storage disease, cirrhosis and hepatocellular carcinoma.

    Iglesias Jorquera E, Tomás Pujante P, Ruiz García G, et al.

    Revista espanola de enfermedades digestivas 2019; (111(2)):168-169 doi:10.17235/reed.2018.5856/2018.

    PMID: 30318896
  7. 7

    The biallelic novel pathogenic variants in AGL gene in a chinese patient with glycogen storage disease type III.

    Wang J, Yu Y, Cai C, et al.

    BMC pediatrics 2022; (22(1)):284 doi:10.1186/s12887-022-03252-y.

    PMID: 35578201
  8. 8

    Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.

    Sentner CP, Hoogeveen IJ, Weinstein DA, et al.

    Journal of inherited metabolic disease 2016; (39(5)):697-704 doi:10.1007/s10545-016-9932-2.

    PMID: 27106217
  9. 9

    A Functional Human Glycogen Debranching Enzyme Encoded by a Synthetic Gene: Its Implications for Glycogen Storage Disease Type III Management.

    Triggiani D, Demurtas OC, Illiano E, et al.

    Protein and peptide letters 2024; (31(7)):519-531 doi:10.2174/0109298665307430240628063339.

    PMID: 39021187
  10. 10

    Molecular architecture and catalytic mechanism of human glycogen debranching enzyme.

    Guan H, Chen H, Geng H, et al.

    Nature communications 2025; (16(1)):5962 doi:10.1038/s41467-025-61077-6.

    PMID: 40593796
  11. 11

    Glycogen Storage Disease in Twins: When Two Lives Reflect One Silent Battle.

    Shah RK, Khan SA, Devkota D, et al.

    Clinical case reports 2026; (14(1)):e71889 doi:10.1002/ccr3.71889.

    PMID: 41567525
  12. 12

    Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring.

    Halaby CA, Young SP, Austin S, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(12)):2686-2694 doi:10.1038/s41436-019-0561-7.

    PMID: 31263214
  13. 13

    Pathological modeling of glycogen storage disease type III with CRISPR/Cas9 edited human pluripotent stem cells.

    Rossiaud L, Fragner P, Barbon E, et al.

    Frontiers in cell and developmental biology 2023; (11()):1163427 doi:10.3389/fcell.2023.1163427.

    PMID: 37250895
  14. 14

    Muscle Ultrasound in Patients with Glycogen Storage Disease Types I and III.

    Verbeek RJ, Sentner CP, Smit GP, et al.

    Ultrasound in medicine & biology 2016; (42(1)):133-42.

    PMID: 26437929
  15. 15

    Data highlighting effects of Ketogenic diet on cardiomyopathy and hepatopathy in Glycogen storage disease Type IIIA.

    Marusic T, Zerjav Tansek M, Sirca Campa A, et al.

    Data in brief 2020; (32()):106205 doi:10.1016/j.dib.2020.106205.

    PMID: 32939375
  16. 16

    Cardiovascular involvement in glycogen storage diseases.

    Pinós T, Cubbon RM, Santalla A, et al.

    Nature reviews. Cardiology 2026; (23(1)):39-59 doi:10.1038/s41569-025-01171-w.

    PMID: 40473899
  17. 17

    Late presentation of glycogen storage disease types Ia and III in children with short stature and hepatomegaly.

    Quackenbush D, Devito J, Garibaldi L, Buryk M

    Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(4)):473-478 doi:10.1515/jpem-2017-0209.

    PMID: 29374762
  18. 18

    The Novel Compound Heterozygous Mutations in the AGL Gene in a Chinese Family With Adult Late-Onset Glycogen Storage Disease Type IIIa.

    Qu Q, Qian Q, Shi J, et al.

    Frontiers in neurology 2020; (11()):554012 doi:10.3389/fneur.2020.554012.

    PMID: 33329302
  19. 19

    Long-term personalized high-protein, high-fat diet in pediatric patients with glycogen storage disease type IIIa: Evaluation of myopathy, metabolic control, physical activity, growth, and dietary compliance.

    Kalkan Uçar S, Altınok YA, Mansuroglu Y, et al.

    Journal of inherited metabolic disease 2024; (47(5)):1001-1017 doi:10.1002/jimd.12741.

    PMID: 38623712
  20. 20

    Liver transplantation in glycogen storage disease type III: A case-series.

    Gay S, Bigot A, d'Alteroche L, et al.

    JIMD reports 2025; (66(1)):e12463 doi:10.1002/jmd2.12463.

    PMID: 39866164

This page explains GSD III subtypes and symptom progression for educational purposes only. Always consult your genetics or metabolic specialist for personal medical advice, dietary changes, and symptom monitoring.

Get notified when new evidence is published on Glycogen storage disease due to glycogen debranching enzyme deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.